PCWG3 (Prostate Cancer Working Group 3) and Oncology Imaging Endpoints
Prostate cancer is one of the most common cancer types in men. With bone as a frequent metastatic site, response assessments for prostate cancer have additional considerations beyond RECIST 1.1. In our upcoming webinar, MERIT will outline the fundamentals of PCWG3 response criteria, data collection, and response assessment using PSMA scan in prostate cancer.
3 key questions
that are answered:
- Which imaging modalities are used for prostate cancer assessment?
- What are the fundamentals of PCWG3 response criteria and data collection?
- How is PSMA being used for newer imaging modalities and response assessments?
Catherine Chintala works at MERIT as a Project Manager in their Oncology division. With 20 years of experience working in clinical trials and the CRO industry, she has expertise managing oncology clinical trials from start up to close out. Catherine works closely with sponsors, designing and implementing processes to meet project timelines and helping to ensure study needs are clearly communicated across key stakeholders. Drawing upon her experience in a variety of indications and response criteria, Catherine can partner with your team to help make your clinical trial a success.
Gene is a Clinical Scientist providing subject matter expertise and helping design and configure MERIT’s flexible oncology reading platform to accommodate various reading paradigms. He has experience in evidence-based patient care and academic research, a background in pharmacy, and 6 years supporting clinical trials. Gene implements software workflows to support oncology trials with response criteria such as RECIST 1.1, iRECIST, Lugano, and RANO, and helps to increase the efficiency and accuracy of clinical data collection for imaging endpoints. He received his Doctor of Pharmacy (Pharm.D.) from the University of Wisconsin-Madison and has a bachelor’s degree in Neurobiology.
Matt is an oncology expert with nearly 15 years of experience including first-hand patient imaging and OEM imaging industry insights. He works closely with Sponsors and CROs, identifying opportunities to provide researchers with optimal data endpoints required for their study goals. Matt holds an MBA and has an undergraduate degree in Nuclear Medicine Technology, with certifications in Nuclear Medicine, Computed Tomography, and Positron Emission Tomography (PET) through the Nuclear Medicine Technology Certification Board (NMTCB).